{ "instance": { "spro-20221231.htm": { "axisCustom": 0, "axisStandard": 34, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 701, "http://xbrl.sec.gov/dei/2022": 39 }, "contextCount": 282, "dts": { "calculationLink": { "local": [ "spro-20221231_cal.xml" ] }, "definitionLink": { "local": [ "spro-20221231_def.xml" ] }, "inline": { "local": [ "spro-20221231.htm" ] }, "labelLink": { "local": [ "spro-20221231_lab.xml" ] }, "presentationLink": { "local": [ "spro-20221231_pre.xml" ] }, "schema": { "local": [ "spro-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 802, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 21, "http://xbrl.sec.gov/dei/2022": 4, "total": 25 }, "keyCustom": 110, "keyStandard": 301, "memberCustom": 59, "memberStandard": 37, "nsprefix": "spro", "nsuri": "http://sperotherapeutics.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Fair Value Measurements and Marketable Securities", "menuCat": "Notes", "order": "10", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecurities", "shortName": "Fair Value Measurements and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Property and Equipment, Net", "menuCat": "Notes", "order": "11", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Leases", "menuCat": "Notes", "order": "12", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "13", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Equity", "menuCat": "Notes", "order": "14", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "15", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:RevenueInterestFinancingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Liability Related to the Sale of Future Royalties", "menuCat": "Notes", "order": "16", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyalties1", "shortName": "Liability Related to the Sale of Future Royalties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:RevenueInterestFinancingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Restructuring", "menuCat": "Notes", "order": "17", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:GrantsFromGovernmentContractsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Government Contracts", "menuCat": "Notes", "order": "20", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContracts", "shortName": "Government Contracts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:GrantsFromGovernmentContractsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - License, Collaboration and Service Agreements", "menuCat": "Notes", "order": "21", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreements", "shortName": "License, Collaboration and Service Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Net Loss per Share", "menuCat": "Notes", "order": "22", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Retirement Plan", "menuCat": "Notes", "order": "23", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan", "shortName": "Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "24", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "25", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:EstimatedUsefulLivesOfAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "26", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:EstimatedUsefulLivesOfAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements and Marketable Securities (Tables)", "menuCat": "Tables", "order": "27", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesTables", "shortName": "Fair Value Measurements and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Property and Equipment, Net (Tables)", "menuCat": "Tables", "order": "28", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "29", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "30", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Share-Based Compensation (Tables)", "menuCat": "Tables", "order": "31", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "spro:RevenueInterestFinancingTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:ScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyalties", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)", "menuCat": "Tables", "order": "32", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesTables", "shortName": "Liability Related to the Sale of Future Royalties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "spro:RevenueInterestFinancingTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:ScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyalties", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:RestructuringChargesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Restructuring (Tables)", "menuCat": "Tables", "order": "33", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:RestructuringChargesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "34", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - License, Collaboration and Service Agreements (Tables)", "menuCat": "Tables", "order": "35", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsTables", "shortName": "License, Collaboration and Service Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Net Loss per Share (Tables)", "menuCat": "Tables", "order": "36", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:EntityIncorporationMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)", "menuCat": "Details", "order": "37", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "spro:EntityIncorporationMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "menuCat": "Details", "order": "38", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:EstimatedUsefulLivesOfAssetsTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_7fc3c9dc-6bdc-4411-8009-c68c28010ba9", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Detail)", "menuCat": "Details", "order": "39", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail", "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:EstimatedUsefulLivesOfAssetsTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_7fc3c9dc-6bdc-4411-8009-c68c28010ba9", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "spro:GrantRevenue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "4", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "spro:GrantRevenue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Financial Assets and Liabilities Measured at Fair Value Recurring Basis (Detail)", "menuCat": "Details", "order": "40", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail", "shortName": "Fair Value Measurements and Marketable Securities - Summary of Financial Assets and Liabilities Measured at Fair Value Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_554a853e-658b-4770-8f64-019864944d6a", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Detail)", "menuCat": "Details", "order": "41", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "shortName": "Fair Value Measurements and Marketable Securities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-6", "lang": null, "name": "spro:FairValueLiabilitiesOfLevel2ToLevel1TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail)", "menuCat": "Details", "order": "42", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail", "shortName": "Fair Value Measurements and Marketable Securities - Summary of Gross Unrealized Gains and Losses of Marketable Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Property and Equipment, Net - Components of Property and Equipment, Net (Detail)", "menuCat": "Details", "order": "43", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "shortName": "Property and Equipment, Net - Components of Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Property and Equipment, Net - Additional Information (Detail)", "menuCat": "Details", "order": "44", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "shortName": "Property and Equipment, Net - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_136f7332-583f-4987-9997-142202f76600", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_06a72098-5544-4b65-9f56-0a7e00a04ae8", "decimals": null, "first": true, "lang": "en-US", "name": "spro:OperatingLeasesExpirationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Leases - Additional Information (Detail)", "menuCat": "Details", "order": "45", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_06a72098-5544-4b65-9f56-0a7e00a04ae8", "decimals": null, "first": true, "lang": "en-US", "name": "spro:OperatingLeasesExpirationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Leases - Summary of Components of Operating Lease Expense (Detail)", "menuCat": "Details", "order": "46", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail", "shortName": "Leases - Summary of Components of Operating Lease Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Detail)", "menuCat": "Details", "order": "47", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail", "shortName": "Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Leases - Summary of Lease Balances Related to Operating and Finance Leases Except Weighted Average Remaining Lease Term And Discount Rate (Detail)", "menuCat": "Details", "order": "48", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail", "shortName": "Leases - Summary of Lease Balances Related to Operating and Finance Leases Except Weighted Average Remaining Lease Term And Discount Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:ScheduleOfLeaseBalancesRelatedToOperatingAndFinanceLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Detail)", "menuCat": "Details", "order": "49", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail", "shortName": "Leases - Summary of Maturity of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_ec4658ba-7170-4a5f-9fb6-22c699fb4bdf", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_ec4658ba-7170-4a5f-9fb6-22c699fb4bdf", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "spro:AccruedExternalResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "menuCat": "Details", "order": "50", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "spro:AccruedExternalResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_fd26e606-196c-4067-b698-a822002cfff5", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Equity Transactions - Underwritten Public Offering - Additional Information (Detail)", "menuCat": "Details", "order": "51", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "shortName": "Equity Transactions - Underwritten Public Offering - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Equity Transactions - Rights Offering - Additional Information (Detail)", "menuCat": "Details", "order": "52", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "shortName": "Equity Transactions - Rights Offering - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Equity - Additional Information (Detail)", "menuCat": "Details", "order": "53", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "shortName": "Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_ca90614a-bbb5-4aa8-a3c0-b1bf517aa48d", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "menuCat": "Details", "order": "54", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Detail)", "menuCat": "Details", "order": "55", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_5c8680e6-a636-4d46-ba98-d8a4d03f0d5c", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Share-Based Compensation - Summary of Activity of Options and RSUs of Performance-Based Options (Details)", "menuCat": "Details", "order": "56", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "shortName": "Share-Based Compensation - Summary of Activity of Options and RSUs of Performance-Based Options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Share-Based Compensation - Summary of Assumptions Used to Determine Fair Value of Stock Option Awards Granted to Employees and Directors (Detail)", "menuCat": "Details", "order": "57", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsUsedToDetermineFairValueOfStockOptionAwardsGrantedToEmployeesAndDirectorsDetail", "shortName": "Share-Based Compensation - Summary of Assumptions Used to Determine Fair Value of Stock Option Awards Granted to Employees and Directors (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Share-Based Compensation - Summary of Stock Option Granted Under Equity Incentive Plans (Detail)", "menuCat": "Details", "order": "58", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail", "shortName": "Share-Based Compensation - Summary of Stock Option Granted Under Equity Incentive Plans (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)", "menuCat": "Details", "order": "59", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail", "shortName": "Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_add26f2f-6bcc-4488-a12d-281f0d90605e", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND STOCKHOLDERS' EQUITY (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3ef84cf7-4951-4544-94eb-4fc650932c8e", "decimals": "-5", "lang": null, "name": "spro:CommonStockIssuedDiscountValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)", "menuCat": "Details", "order": "60", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "shortName": "Share-Based Compensation - Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_50979feb-1f18-45e3-8a5d-a3c6f492030a", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Liability Related to the Sale of Future Royalties- Additional Information (Detail)", "menuCat": "Details", "order": "61", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "shortName": "Liability Related to the Sale of Future Royalties- Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "spro:RevenueInterestFinancingTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-6", "lang": null, "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Liability Related to the Sale of Future Royalties - Schedule of Changes in the Liability Related to the Sale of Future Royalties (Details)", "menuCat": "Details", "order": "62", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails", "shortName": "Liability Related to the Sale of Future Royalties - Schedule of Changes in the Liability Related to the Sale of Future Royalties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "spro:ScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyalties", "div", "spro:RevenueInterestFinancingTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_49351c45-1c8b-4469-89b0-6b0044e635ac", "decimals": "-3", "lang": null, "name": "spro:RoyaltyLiabilityBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Non-Controlling Interests - Spero Gyrase - Additional Information (Detail)", "menuCat": "Details", "order": "63", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "shortName": "Non-Controlling Interests - Spero Gyrase - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Restructuring (Additional Information) (Details)", "menuCat": "Details", "order": "64", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "shortName": "Restructuring (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Restructuring - Restructuring charges (Details)", "menuCat": "Details", "order": "65", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails", "shortName": "Restructuring - Restructuring charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Restructuring - Schedule of Restructuring charges included in Accrued expenses and other current liabilities (Details)", "menuCat": "Details", "order": "66", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringScheduleOfRestructuringChargesIncludedInAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Restructuring - Schedule of Restructuring charges included in Accrued expenses and other current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "lang": null, "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Income Taxes - Additional Information (Detail)", "menuCat": "Details", "order": "67", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss before Income Taxes (Detail)", "menuCat": "Details", "order": "68", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail", "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Loss before Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Detail)", "menuCat": "Details", "order": "69", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail", "shortName": "Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "7", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "lang": null, "name": "spro:NonCashLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Income Taxes - Net Deferred Tax Assets (Detail)", "menuCat": "Details", "order": "70", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail", "shortName": "Income Taxes - Net Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_3cf520e0-498f-457d-a035-ccb073fea3a9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Detail)", "menuCat": "Details", "order": "71", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail", "shortName": "Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "lang": null, "name": "spro:ValuationAllowanceDeferredTaxAssetIncreaseInAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Government Contracts - Additional Information (Detail)", "menuCat": "Details", "order": "72", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "shortName": "Government Contracts - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "spro:GrantsFromGovernmentContractsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_9ed90a56-79e6-4efc-9f5d-e008532637ea", "decimals": "-5", "lang": null, "name": "spro:MaximumPotentialFundingFromGovernmentContract", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenueCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - License, Collaboration and Service Agreements - Additional Information (Detail)", "menuCat": "Details", "order": "73", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "shortName": "License, Collaboration and Service Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-5", "lang": null, "name": "spro:RemainingTransactionPriceAllocatedToPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-5", "first": true, "lang": null, "name": "spro:MilestonePaymentUponSubmissionOfANewDrugApplication", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - License, Collaboration and Service Agreements - Schedule of remaining potential milestone payments (Details)", "menuCat": "Details", "order": "74", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "shortName": "License, Collaboration and Service Agreements - Schedule of remaining potential milestone payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_befbf307-79da-472d-b571-9230f4e21bbe", "decimals": "-8", "lang": null, "name": "spro:SalesMilestoneEvents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail)", "menuCat": "Details", "order": "75", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "shortName": "Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Net Loss per Share - Summary of Shares Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)", "menuCat": "Details", "order": "76", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "shortName": "Net Loss per Share - Summary of Shares Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_38f6c692-f27e-4f52-b1fd-18108abae747", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Retirement Plan - Additional Information (Detail)", "menuCat": "Details", "order": "77", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetail", "shortName": "Retirement Plan - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "p", "spro:GrantsFromGovernmentContractsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_ae492ce8-d2b3-4276-b983-acf97e6539d5", "decimals": "-5", "first": true, "lang": null, "name": "spro:PotentialAmountAdditionalFundingAwarded", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Subsequent Events - Additional Information (Detail)", "menuCat": "Details", "order": "78", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail", "shortName": "Subsequent Events - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_8080a9f0-b76f-456e-80f5-905f490f6eea", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Nature of the Business and Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "spro-20221231.htm", "contextRef": "C_d64ec26c-84aa-4150-aa1b-15905bc6c918", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 106, "tag": { "country_AU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AUSTRALIA", "terseLabel": "Australia [Member]" } } }, "localname": "AU", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r665", "r666", "r667" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r665", "r666", "r667" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r665", "r666", "r667" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r665", "r666", "r667" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "verboseLabel": "State of incorporation" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r669" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r670" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r665", "r666", "r667" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "spro_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "spro_AccruedExternalResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 0.0, "parentTag": "spro_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued external research and development expenses current.", "label": "Accrued External Research And Development Expenses Current", "terseLabel": "Accrued external research and development expenses" } } }, "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "spro_AccruedRestructuringExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued restructuring expenses", "label": "Accrued restructuring expenses" } } }, "localname": "AccruedRestructuringExpenses", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "spro_AdditionalInvestmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional investment amount", "label": "Additional investment amount" } } }, "localname": "AdditionalInvestmentAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_AdditionalMilestonePaymentsReceivableUponAchievementOfCertainDevelopmentalRegulatoryAndSalesMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional milestone payments receivable upon achievement of certain developmental regulatory and sales milestone.", "label": "Additional Milestone Payments Receivable Upon Achievement Of Certain Developmental Regulatory And Sales Milestone", "terseLabel": "Receivable amount upon achievement of certain milestone" } } }, "localname": "AdditionalMilestonePaymentsReceivableUponAchievementOfCertainDevelopmentalRegulatoryAndSalesMilestone", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_AdditionalNumberOfCommonStockIssuable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional number of common stock issuable.", "label": "Additional Number Of Common Stock Issuable", "terseLabel": "Additional number of common stock issuable" } } }, "localname": "AdditionalNumberOfCommonStockIssuable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "spro_AdjustmentsToAdditionalPaidInCapitalAccretionOfConvertiblePreferredStockToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital accretion of convertible preferred stock to redemption value.", "label": "Adjustments To Additional Paid In Capital Accretion Of Convertible Preferred Stock To Redemption Value", "terseLabel": "Accretion of Series C preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAccretionOfConvertiblePreferredStockToRedemptionValue", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "spro_AggregateRetentionAwardsCashBonus": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate Retention Awards Cash Bonus", "label": "Aggregate Retention Awards Cash Bonus" } } }, "localname": "AggregateRetentionAwardsCashBonus", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "spro_AgreementTerminationPeriodUponWrittenNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement termination period upon written notice.", "label": "Agreement Termination Period Upon Written Notice", "terseLabel": "Agreement termination period upon written notice" } } }, "localname": "AgreementTerminationPeriodUponWrittenNotice", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_AmountOfAgreedPurchaseSharesAndNotSubscribedSharesValueUnderRightsOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of agreed purchase shares and not subscribed shares value under rights offering.", "label": "Amount Of Agreed Purchase Shares And Not Subscribed Shares Value Under Rights Offering", "terseLabel": "Amount of agreed to purchase offered shares and not subscribed shares value under rights offering" } } }, "localname": "AmountOfAgreedPurchaseSharesAndNotSubscribedSharesValueUnderRightsOffering", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_AnnualRentalEscalationAndTenantIncentives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Annual rental escalation and tenant incentives.", "label": "Annual Rental Escalation And Tenant Incentives", "terseLabel": "Annual rent escalations and tenant incentives" } } }, "localname": "AnnualRentalEscalationAndTenantIncentives", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_AntidilutiveSecuritiesExcludedFromComputationEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antidilutive Securities Excluded From Computation Earnings Per Share [Abstract]", "label": "Antidilutive Securities Excluded From Computation Earnings Per Share [Abstract]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationEarningsPerShareAbstract", "nsuri": "http://sperotherapeutics.com/20221231", "xbrltype": "stringItemType" }, "spro_AssetsLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets lessee.", "label": "Assets Lessee [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsLesseeAbstract", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "stringItemType" }, "spro_Asu201813Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASU No.2018-13 member", "label": "ASU No.2018-13 [Member]", "terseLabel": "ASU No. 2018-13 [Member]" } } }, "localname": "Asu201813Member", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_AtTheMarketOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-the-market offering program.", "label": "At The Market Offering Program [Member]", "terseLabel": "At-The-Market Offering Program [Member]" } } }, "localname": "AtTheMarketOfferingProgramMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_AuthorizedCommonStockValueAvailableForIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Authorized common stock value available for issuance.", "label": "Authorized Common Stock Value Available For Issuance", "terseLabel": "Common stock available for issuance" } } }, "localname": "AuthorizedCommonStockValueAvailableForIssuance", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_AuthorizedCommonStockValueRemainingAvailableForIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Authorized common stock value remaining available for issuance.", "label": "Authorized Common Stock Value Remaining Available For Issuance", "terseLabel": "Common stock value remaining available for issuance" } } }, "localname": "AuthorizedCommonStockValueRemainingAvailableForIssuance", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_AviragenTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aviragen Therapeutics Inc.", "label": "Aviragen Therapeutics Inc [Member]", "terseLabel": "Aviragen Therapeutics, Inc. [Member]" } } }, "localname": "AviragenTherapeuticsIncMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_AwardReceivedForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Award received for research and development.", "label": "Award Received For Research And Development", "terseLabel": "Award received for clinical development" } } }, "localname": "AwardReceivedForResearchAndDevelopment", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_BasePeriodContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base period contracts.", "label": "Base Period Contracts [Member]", "terseLabel": "Base Period Contracts [Member]" } } }, "localname": "BasePeriodContractsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_BeneficialConversionFeatureOfStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Beneficial conversion feature of stock.", "label": "Beneficial Conversion Feature Of Stock", "terseLabel": "Beneficial conversion feature of Series C preferred stock" } } }, "localname": "BeneficialConversionFeatureOfStock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "spro_BiomedicalAdvancedResearchAndDevelopmentAuthorityAndDefenseThreatReductionAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biomedical Advanced Research And Development Authority And The Defense Threat Reduction Agency.", "label": "Biomedical Advanced Research And Development Authority And Defense Threat Reduction Agency [Member]", "terseLabel": "BARDA and DTRA [Member]" } } }, "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityAndDefenseThreatReductionAgencyMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_BiomedicalAdvancedResearchAndDevelopmentAuthorityAndSperosAchievementOfSpecifiedMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biomedical advanced research and development authority and Spero\u2019s achievement of specified milestones.", "label": "Biomedical Advanced Research And Development Authority And Speros Achievement Of Specified Milestones [Member]", "terseLabel": "BARDA and Speros Achievement of Specified Milestones [Member]" } } }, "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityAndSperosAchievementOfSpecifiedMilestonesMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biomedical Advanced Research and Development Authority.", "label": "Biomedical Advanced Research And Development Authority [Member]", "terseLabel": "BARDA [Member]" } } }, "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_CARESActEligibleCostRecoveryPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES act eligible cost-recovery period.", "label": "C A R E S Act Eligible Cost Recovery Period", "terseLabel": "CARES act eligible cost-recovery period" } } }, "localname": "CARESActEligibleCostRecoveryPeriod", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_CARESActEliminatedPercentageOnLimitationOfTaxableIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES act eliminated percentage on limitation of taxable income.", "label": "C A R E S Act Eliminated Percentage On Limitation Of Taxable Income", "terseLabel": "CARES act eliminated percentage on limitation of taxable income" } } }, "localname": "CARESActEliminatedPercentageOnLimitationOfTaxableIncome", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_CARESActNetOperatingLossCarrybackPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES act net operating loss carryback period.", "label": "C A R E S Act Net Operating Loss Carryback Period", "terseLabel": "CARES act net operating loss carryback period" } } }, "localname": "CARESActNetOperatingLossCarrybackPeriod", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_CARESActPercentageOfAdjustedTaxableIncomePlusBusinessInterestIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES Act percentage of adjusted taxable income plus business interest income.", "label": "C A R E S Act Percentage Of Adjusted Taxable Income Plus Business Interest Income", "terseLabel": "Percentage of adjusted taxable income plus business interest income" } } }, "localname": "CARESActPercentageOfAdjustedTaxableIncomePlusBusinessInterestIncome", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_CARESActPercentageOfBonusDepreciation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES act percentage of bonus depreciation.", "label": "C A R E S Act Percentage Of Bonus Depreciation", "terseLabel": "CARES act percentage of bonus depreciation" } } }, "localname": "CARESActPercentageOfBonusDepreciation", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_CARESActPercentageOfCorporateCharitableDeductionLimitationOnTaxableIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES Act percentage of corporate charitable deduction limitation on taxable income.", "label": "C A R E S Act Percentage Of Corporate Charitable Deduction Limitation On Taxable Income", "terseLabel": "CARES act Percentage of corporate charitable deduction limitation on taxable income" } } }, "localname": "CARESActPercentageOfCorporateCharitableDeductionLimitationOnTaxableIncome", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_CARESActPercentageOfLimitationOnAdjustedTaxableIncomePlusBusinessInterestIncomeUnderTaxCutAndJobsAct2017": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES act percentage of limitation on adjusted taxable income plus business interest income under tax cut and jobs act 2017.", "label": "C A R E S Act Percentage Of Limitation On Adjusted Taxable Income Plus Business Interest Income Under Tax Cut And Jobs Act2017", "terseLabel": "Percentage of limitation on adjusted taxable income plus business interest income under 2017 tax act" } } }, "localname": "CARESActPercentageOfLimitationOnAdjustedTaxableIncomePlusBusinessInterestIncomeUnderTaxCutAndJobsAct2017", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_CambridgeMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cambridge Massachusetts.", "label": "Cambridge Massachusetts [Member]", "terseLabel": "Cambridge, Massachusetts [Member]" } } }, "localname": "CambridgeMassachusettsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_CantabAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantab Agreements.", "label": "Cantab Agreements [Member]", "terseLabel": "Cantab Agreements [Member]" } } }, "localname": "CantabAgreementsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_CantabAntiInfectivesLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantab Anti Infectives Ltd.", "label": "Cantab Anti Infectives Ltd [Member]", "terseLabel": "Cantab Anti Infectives Ltd. [Member]" } } }, "localname": "CantabAntiInfectivesLtdMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_CantabRelatedAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantab Related Agreements [Member]", "label": "Cantab Related Agreements [Member]", "terseLabel": "Cantab Related Agreements [Member]" } } }, "localname": "CantabRelatedAgreementsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_CantorFitzgeraldCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantor Fitzgerald & Co.", "label": "Cantor Fitzgerald Co [Member]", "terseLabel": "Cantor Fitzgerald & Co [Member]" } } }, "localname": "CantorFitzgeraldCoMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_CaresActCharitableDeductionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES Act Charitable Deduction Description", "label": "CARES Act Charitable Deduction Description" } } }, "localname": "CaresActCharitableDeductionDescription", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_CashBonus": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Bonus", "label": "Cash Bonus" } } }, "localname": "CashBonus", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "spro_ChangeInSubsequentPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in subsequent payments", "label": "Change in subsequent payments" } } }, "localname": "ChangeInSubsequentPayments", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_ChangeOfControlValueInExcessAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change of Control value in excess amount", "label": "Change of Control Value in Excess Amount" } } }, "localname": "ChangeOfControlValueInExcessAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ClinicalTrialAndOtherResearchContractCostsAndAccrualsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical trial and other research contract costs and accruals policy.", "label": "Clinical Trial And Other Research Contract Costs And Accruals Policy Policy [Text Block]", "terseLabel": "Clinical Trial and other Research Contract Costs and Accruals" } } }, "localname": "ClinicalTrialAndOtherResearchContractCostsAndAccrualsPolicyPolicyTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "spro_CommercialManufacturingFacilityAmortizationServicePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial manufacturing facility amortization service period.", "label": "Commercial Manufacturing Facility Amortization Service Period", "terseLabel": "Supervision fee amortization service period" } } }, "localname": "CommercialManufacturingFacilityAmortizationServicePeriod", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_CommercialMilestonePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Milestone Payments [Member]", "label": "Commercial Milestone Payments [Member]", "terseLabel": "Commercial milestone payments" } } }, "localname": "CommercialMilestonePaymentsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails" ], "xbrltype": "domainItemType" }, "spro_CommonStockAndSeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock and series A preferred stock.", "label": "Common Stock And Series C Preferred Stock [Member]", "terseLabel": "Common Stock and Series C Preferred Stock [Member]" } } }, "localname": "CommonStockAndSeriesCPreferredStockMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_CommonStockIssuedDiscountValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "common stock issued discount value", "label": "common stock issued discount value" } } }, "localname": "CommonStockIssuedDiscountValue", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "monetaryItemType" }, "spro_CommonStockIssuedPremiumValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common Stock Issued Premium Value.", "label": "Common Stock Issued Premium Value", "terseLabel": "Premium on issued of common stock" } } }, "localname": "CommonStockIssuedPremiumValue", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "monetaryItemType" }, "spro_CommonStockPurchaseFromEachSubscriptionRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock purchase from each subscription right.", "label": "Common Stock Purchase From Each Subscription Right", "terseLabel": "Right to purchase common stock shares" } } }, "localname": "CommonStockPurchaseFromEachSubscriptionRight", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "spro_ContractTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract term.", "label": "Contract Term", "terseLabel": "Contract term" } } }, "localname": "ContractTerm", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_ContractTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract termination period.", "label": "Contract Termination Period", "terseLabel": "Contract termination period" } } }, "localname": "ContractTerminationPeriod", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_ContractTerminationPeriodIfNoMaterialDevelopmentOrCommercializationOccurs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract termination period if no material development or commercialization occurs.", "label": "Contract Termination Period If No Material Development Or Commercialization Occurs", "terseLabel": "Contract termination period if no material development or commercialization occurs" } } }, "localname": "ContractTerminationPeriodIfNoMaterialDevelopmentOrCommercializationOccurs", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_CoveringPeriodOfNonDiluitveFunding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covering period of non-diluitve funding.", "label": "Covering Period Of Non Diluitve Funding", "terseLabel": "Non-dilutive funding period" } } }, "localname": "CoveringPeriodOfNonDiluitveFunding", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_DateOfMinimumAggregatePaymentReceivedThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date Of Minimum Aggregate Payment Received Threshold", "label": "Date Of Minimum Aggregate Payment Received Threshold", "terseLabel": "Date Of Minimum Aggregate Payment Received Threshold" } } }, "localname": "DateOfMinimumAggregatePaymentReceivedThreshold", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "spro_DeemedDividendsRelatedToImmediateAccretionOfBeneficialConversionFeatureOfStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deemed dividends related to immediate accretion of beneficial conversion feature of stock.", "label": "Deemed Dividends Related To Immediate Accretion Of Beneficial Conversion Feature Of Stock", "terseLabel": "Deemed dividends related to immediate accretion of beneficial conversion feature of Series C preferred stock" } } }, "localname": "DeemedDividendsRelatedToImmediateAccretionOfBeneficialConversionFeatureOfStock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "spro_DefenseThreatReductionAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defense Threat Reduction Agency.", "label": "Defense Threat Reduction Agency [Member]", "terseLabel": "DTRA [Member]" } } }, "localname": "DefenseThreatReductionAgencyMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax credit carryforwards research and development.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research And Development", "terseLabel": "FederalTax credit carryforward" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramsAndJointWarfighterMedicalResearchProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DoD, Congressionally Directed Medical Research Programs and Joint Warfighter Medical Research Program.", "label": "Department Of Defense Congressionally Directed Medical Research Programs And Joint Warfighter Medical Research Program [Member]", "terseLabel": "DoD, CDMRP and JWMRP [Member]" } } }, "localname": "DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramsAndJointWarfighterMedicalResearchProgramMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_DiscountOnObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on Obligations.", "label": "Discount on Obligations", "terseLabel": "Discount on Performance of Obligations" } } }, "localname": "DiscountOnObligations", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_EffectiveTaxIncentiveRateRelatedToResearchAndDevelopment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective tax incentive rate related to research and development.", "label": "Effective Tax Incentive Rate Related To Research And Development", "terseLabel": "Percentage of refundable tax incentive" } } }, "localname": "EffectiveTaxIncentiveRateRelatedToResearchAndDevelopment", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_EmbeddedFinanceLeasesFixedAssetsRelatedPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Embedded finance leases fixed assets related payments.", "label": "Embedded Finance Leases Fixed Assets Related Payments", "terseLabel": "Embedded finance leases fixed assets related payments" } } }, "localname": "EmbeddedFinanceLeasesFixedAssetsRelatedPayments", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_EntityIncorporationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity incorporation month and year.", "label": "Entity Incorporation Month And Year", "terseLabel": "Entity incorporation month and year" } } }, "localname": "EntityIncorporationMonthAndYear", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "spro_EquityTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Transactions.", "label": "Equity Transactions [Text Block]", "terseLabel": "Equity Transactions" } } }, "localname": "EquityTransactionsTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactions" ], "xbrltype": "textBlockItemType" }, "spro_EstablishChangeOfControlDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Establish change of control derivative liability", "label": "Establish change of control derivative liability" } } }, "localname": "EstablishChangeOfControlDerivativeLiability", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "monetaryItemType" }, "spro_EstimatedUsefulLivesOfAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated useful lives of assets.", "label": "Estimated Useful Lives Of Assets Table [Text Block]", "terseLabel": "Estimated Useful Lives of Assets" } } }, "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "spro_EverestLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Everest license agreement.", "label": "Everest License Agreement [Member]", "terseLabel": "Everest License Agreement [Member]" } } }, "localname": "EverestLicenseAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_ExclusiveOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive option.", "label": "Exclusive Option [Member]", "terseLabel": "Exclusive Option [Member]" } } }, "localname": "ExclusiveOptionMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "domainItemType" }, "spro_ExecutiveRetentionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive Retention Awards Member", "label": "Executive Retention Awards Member" } } }, "localname": "ExecutiveRetentionAwardsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "spro_ExtendedContractTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extended contract term.", "label": "Extended Contract Term", "terseLabel": "Contract term extended" } } }, "localname": "ExtendedContractTerm", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_FairValueLiabilitiesOfLevel2ToLevel1TransfersAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Liabilities of Level 2 to Level 1 Transfers Amount", "label": "Fair Value, Liabilities of Level 2 to Level 1 Transfers Amount" } } }, "localname": "FairValueLiabilitiesOfLevel2ToLevel1TransfersAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_FirstOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First option.", "label": "First Option [Member]", "terseLabel": "First Option [Member]" } } }, "localname": "FirstOptionMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_GatesMRIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gates MRI.", "label": "Gates M R I [Member]", "terseLabel": "Gates MRI [Member]" } } }, "localname": "GatesMRIMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_GlaxoGroupLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glaxo Group Limited [Member]", "label": "Glaxo Group Limited [Member]" } } }, "localname": "GlaxoGroupLimitedMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_GlaxoSmithKlineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glaxo Smith Kline [Member]", "label": "Glaxo Smith Kline [Member]" } } }, "localname": "GlaxoSmithKlineMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_GovernmentContractsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government contracts.", "label": "Government Contracts [Line Items]", "terseLabel": "Government Contracts [Line Items]" } } }, "localname": "GovernmentContractsLineItems", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_GovernmentContractsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government Contracts.", "label": "Government Contracts [Table]", "terseLabel": "Government Contracts [Table]" } } }, "localname": "GovernmentContractsTable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_GovernmentTaxIncentivesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government tax incentives policy", "label": "Government Tax Incentives Policy Policy [Text Block]", "terseLabel": "Government Tax Incentives" } } }, "localname": "GovernmentTaxIncentivesPolicyPolicyTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "spro_GrantRevenue": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 0.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Grant revenue.", "label": "Grant Revenue", "terseLabel": "Grant revenue" } } }, "localname": "GrantRevenue", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "spro_GrantsFromGovernmentContractsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grants from government contracts disclosure.", "label": "Grants From Government Contracts Disclosure [Text Block]", "terseLabel": "Government Contracts" } } }, "localname": "GrantsFromGovernmentContractsDisclosureTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContracts" ], "xbrltype": "textBlockItemType" }, "spro_GskLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GSK License Agreement [Member]", "label": "GSK License Agreement [Member]" } } }, "localname": "GskLicenseAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_GskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GSK [Member]", "label": "GSK [Member]", "terseLabel": "GSK [Member]" } } }, "localname": "GskMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "spro_GskSpaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GSK SPA [Member]", "label": "GSK SPA [Member]", "terseLabel": "GSK SPA [Member]" } } }, "localname": "GskSpaMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_HardCapitalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Hard capital amount", "label": "Hard capital amount" } } }, "localname": "HardCapitalAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_HealthcareRoyaltyManagementLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare royalty management, llc member.", "label": "HealthCare Royalty Management, LLC [Member]", "terseLabel": "HCR [Member]" } } }, "localname": "HealthcareRoyaltyManagementLlcMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_HumanCapitalManagementCommitteeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Human Capital Management Committee [Member]", "label": "Human Capital Management Committee [Member]" } } }, "localname": "HumanCapitalManagementCommitteeMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "spro_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_IncreaseDecreaseInTaxIncentivesReceivable": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in tax incentive receivable, which represents the amount due from tax authorities.", "label": "Increase Decrease In Tax Incentives Receivable", "negatedLabel": "Tax incentive receivables" } } }, "localname": "IncreaseDecreaseInTaxIncentivesReceivable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_IncreaseInOverallPotentialAward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in overall potential award.", "label": "Increase In Overall Potential Award", "terseLabel": "Overall potential award increased" } } }, "localname": "IncreaseInOverallPotentialAward", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_InitialInvestmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial investment amount", "label": "Initial investment amount" } } }, "localname": "InitialInvestmentAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_InitialPaymentsToPerformTheObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial Payments to Perform the Obligations.", "label": "Initial Payments to Perform the Obligations", "terseLabel": "Initial Payments Amount to Perform the Obligations" } } }, "localname": "InitialPaymentsToPerformTheObligations", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_Initialinvestmentamountinterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "InitialInvestmentAmountInterest", "label": "InitialInvestmentAmountInterest", "terseLabel": "Initial investment amount interest" } } }, "localname": "Initialinvestmentamountinterest", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_InterestExpenseRelatedToTheSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest expense related to the sale of future royalties", "label": "Interest expense related to the sale of future royalties" } } }, "localname": "InterestExpenseRelatedToTheSaleOfFutureRoyalties", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "spro_InvestmentAmountFunded": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment amount funded", "label": "Investment amount funded" } } }, "localname": "InvestmentAmountFunded", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_IssuanceOfCommonStockUponTheVestingOfRsus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon the vesting of RSUs", "label": "Issuance of common stock upon the vesting of RSUs" } } }, "localname": "IssuanceOfCommonStockUponTheVestingOfRsus", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "spro_Issuanceofcommonstockuponthevestingofrsu": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "IssuanceOfCommonStockUponTheVestingOfRsu", "label": "IssuanceOfCommonStockUponTheVestingOfRsu" } } }, "localname": "Issuanceofcommonstockuponthevestingofrsu", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "spro_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "domainItemType" }, "spro_LeaseExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration term.", "label": "Lease Expiration Term", "terseLabel": "Lease expiration term" } } }, "localname": "LeaseExpirationTerm", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "spro_LiabilitiesAndStockholdersEquityAuthorizedOfferingValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities and stockholders equity authorized offering value.", "label": "Liabilities And Stockholders Equity Authorized Offering Value", "terseLabel": "Authorized offering value" } } }, "localname": "LiabilitiesAndStockholdersEquityAuthorizedOfferingValue", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities lessee.", "label": "Liabilities Lessee [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesLesseeAbstract", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "stringItemType" }, "spro_LiabilityRelatedToTheSaleOfFutureRoyaltiesNonCurrent": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability related to the sale of future royalties, non-current", "label": "Liability related to the sale of future royalties, non-current", "terseLabel": "Liability related to the sale of future royalties" } } }, "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesNonCurrent", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementFixedAssetsRelatedPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement fixed assets related payments.", "label": "License Agreement Fixed Assets Related Payments", "terseLabel": "License agreement fixed assets related payments" } } }, "localname": "LicenseAgreementFixedAssetsRelatedPayments", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementFutureMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement future milestone payments.", "label": "License Agreement Future Milestone Payments", "terseLabel": "Future milestone payments" } } }, "localname": "LicenseAgreementFutureMilestonePayments", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementMilestonePaymentUponCompletionAndDeliveryOfResultsOfClinicalStudy": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payment upon completion and delivery of results of a clinical study.", "label": "License Agreement Milestone Payment Upon Completion And Delivery Of Results Of Clinical Study", "terseLabel": "Potential milestone payments upon completion and delivery of results of a clinical study" } } }, "localname": "LicenseAgreementMilestonePaymentUponCompletionAndDeliveryOfResultsOfClinicalStudy", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementMilestonePaymentsUponAchievementOfClinicalAndRegulatoryMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments upon achievement of clinical and regulatory milestones.", "label": "License Agreement Milestone Payments Upon Achievement Of Clinical And Regulatory Milestones", "terseLabel": "Potential milestone payment upon achievement of specified clinical and regulatory milestones" } } }, "localname": "LicenseAgreementMilestonePaymentsUponAchievementOfClinicalAndRegulatoryMilestones", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndCommercialMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments upon achievement of specified clinical, regulatory and commercial milestones.", "label": "License Agreement Milestone Payments Upon Achievement Of Specified Clinical Regulatory And Commercial Milestones", "terseLabel": "Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones" } } }, "localname": "LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndCommercialMilestones", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndOtherMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments upon achievement of specified clinical, regulatory and other milestones.", "label": "License Agreement Milestone Payments Upon Achievement Of Specified Clinical Regulatory And Other Milestones", "terseLabel": "Potential milestone payment upon achievement of specified clinical, regulatory and other milestones" } } }, "localname": "LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndOtherMilestones", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedCommercialMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments upon achievement of specified commercial milestone.", "label": "License Agreement Milestone Payments Upon Achievement Of Specified Commercial Milestone", "terseLabel": "Potential milestone payment upon achievement of specified commercial milestone" } } }, "localname": "LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedCommercialMilestone", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementMilestonePaymentsUponAchievementSpecifiedPivotalCondition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments upon achievement of specified pivotal condition.", "label": "License Agreement Milestone Payments Upon Achievement Specified Pivotal Condition", "terseLabel": "Potential milestone payments upon achievement of specified condition" } } }, "localname": "LicenseAgreementMilestonePaymentsUponAchievementSpecifiedPivotalCondition", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementMilestonePaymentsUponClosingOfInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payments upon closing of initial public offering.", "label": "License Agreement Milestone Payments Upon Closing Of Initial Public Offering", "terseLabel": "Potential milestone payment upon closing of initial public offering" } } }, "localname": "LicenseAgreementMilestonePaymentsUponClosingOfInitialPublicOffering", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementPaymentOfResearchAndDevelopmentExpenseRelatedToAchievementOfRegulatoryMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement payment of research and development expense related to achievement of regulatory milestones.", "label": "License Agreement Payment Of Research And Development Expense Related To Achievement Of Regulatory Milestones", "terseLabel": "License agreement payment of research and development expense related to achievement of regulatory milestones" } } }, "localname": "LicenseAgreementPaymentOfResearchAndDevelopmentExpenseRelatedToAchievementOfRegulatoryMilestones", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAgreementResearchAndDevelopmentExpenseRelatedToAchievementOfRegulatoryMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreement research and development expense related to achievement of regulatory milestones.", "label": "License Agreement Research And Development Expense Related To Achievement Of Regulatory Milestones", "terseLabel": "License agreement research and development expense related to achievement of regulatory milestones" } } }, "localname": "LicenseAgreementResearchAndDevelopmentExpenseRelatedToAchievementOfRegulatoryMilestones", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_LicenseAndKnowHowTransferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and know-how transfer member", "label": "License and Know-How Transfer [Member]", "terseLabel": "License and Know-How Transfer [Member]" } } }, "localname": "LicenseAndKnowHowTransferMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "domainItemType" }, "spro_LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on extinguishment of liability related to the sale of future royalties", "label": "Loss on extinguishment of liability related to the sale of future royalties", "negatedLabel": "Loss on extinguishment of liability related to the sale of future royalties", "terseLabel": "Loss on extinguishment of liability related to the sale of future royalties" } } }, "localname": "LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "spro_MaximumPercentageOfCommonStockHoldingUponConversionOfPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of common stock holding upon conversion of preferred stock.", "label": "Maximum Percentage Of Common Stock Holding Upon Conversion Of Preferred Stock", "terseLabel": "Maximum percentage of common stock holding upon conversion of preferred stock" } } }, "localname": "MaximumPercentageOfCommonStockHoldingUponConversionOfPreferredStock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_MaximumPotentialFundingFromGovernmentContract": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum potential funding from government contract", "label": "Maximum Potential Funding From Government Contract", "terseLabel": "Maximum potential funding from government contract" } } }, "localname": "MaximumPotentialFundingFromGovernmentContract", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_MaximumReceivedFundAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum received fund amount.", "label": "Maximum Received Fund Amount", "terseLabel": "Maximum received fund" } } }, "localname": "MaximumReceivedFundAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_MeijiLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Meiji license agreement.", "label": "Meiji License Agreement [Member]", "terseLabel": "Meiji License Agreement [Member]" } } }, "localname": "MeijiLicenseAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_MilestonePaymentUponSubmissionOfANewDrugApplication": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment upon submission of a new drug application.", "label": "Milestone Payment Upon Submission of a New Drug Application", "terseLabel": "Milestone payment" } } }, "localname": "MilestonePaymentUponSubmissionOfANewDrugApplication", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_MilestonesPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestones payment received", "label": "Milestones payment received", "terseLabel": "milestones payment received" } } }, "localname": "MilestonesPaymentReceived", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_NatureOfBusinessAndBasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of business and basis of presentation.", "label": "Nature Of Business And Basis Of Presentation [Abstract]" } } }, "localname": "NatureOfBusinessAndBasisOfPresentationAbstract", "nsuri": "http://sperotherapeutics.com/20221231", "xbrltype": "stringItemType" }, "spro_NatureOfBusinessAndBasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of business and basis of presentation.", "label": "Nature Of Business And Basis Of Presentation [Line Items]", "terseLabel": "Nature Of Business And Basis Of Presentation [Line Items]" } } }, "localname": "NatureOfBusinessAndBasisOfPresentationLineItems", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_NatureOfBusinessAndBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of business and basis of presentation.", "label": "Nature Of Business And Basis Of Presentation [Table]", "terseLabel": "Nature Of Business And Basis Of Presentation [Table]" } } }, "localname": "NatureOfBusinessAndBasisOfPresentationTable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_NdaSubmissionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NDA Submission [Member]", "label": "NDA Submission [Member]", "terseLabel": "NDA Submission [Member]" } } }, "localname": "NdaSubmissionMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails" ], "xbrltype": "domainItemType" }, "spro_NiaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NIAID.", "label": "Niaid [Member]", "terseLabel": "Niaid [Member]" } } }, "localname": "NiaidMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_NonCashAmountOfRightOfUseAssetAndLeaseObligationIncurred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non cash amount of right of use asset and lease obligation incurred.", "label": "Non Cash Amount Of Right Of Use Asset And Lease Obligation Incurred", "terseLabel": "Right-of-use asset and lease obligation recorded upon commencement or amendment of lease agreements" } } }, "localname": "NonCashAmountOfRightOfUseAssetAndLeaseObligationIncurred", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "spro_NonCashAmountsResultingFromTheMeasurementOfTheLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non cash amounts resulting from the measurement of the lease liabilities.", "label": "Non Cash Amounts Resulting From The Measurement Of The Lease Liabilities [Abstract]", "terseLabel": "Non-cash amounts resulting from the measurement of the lease liabilities:" } } }, "localname": "NonCashAmountsResultingFromTheMeasurementOfTheLeaseLiabilitiesAbstract", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "spro_NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash interest expense associated with the sale of future royalties", "label": "Non-cash interest expense associated with the sale of future royalties", "terseLabel": "Non-cash interest expense associated with the sale of future royalties" } } }, "localname": "NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_NonCashLeaseCost": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash lease cost.", "label": "Non Cash Lease Cost", "terseLabel": "Non-cash lease cost" } } }, "localname": "NonCashLeaseCost", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_NonRefundableSupervisionFeeRelatedToCommercialManufacturingFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-refundable supervision fee related to commercial manufacturing facility.", "label": "Non Refundable Supervision Fee Related To Commercial Manufacturing Facility", "terseLabel": "Non-refundable supervision fee related to commercial manufacturing facility" } } }, "localname": "NonRefundableSupervisionFeeRelatedToCommercialManufacturingFacility", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_NonRefundableUpFrontPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non refundable up front payment received.", "label": "Non Refundable Up Front Payment Received", "terseLabel": "Nonrefundable upfront payments" } } }, "localname": "NonRefundableUpFrontPaymentReceived", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_NorthernExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Northern exchange agreement.", "label": "Northern Exchange Agreement [Member]", "terseLabel": "Northern Exchange Agreement [Member]" } } }, "localname": "NorthernExchangeAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_NorthernLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Northern license agreement.", "label": "Northern License Agreement [Member]", "terseLabel": "Northern License Agreement [Member]" } } }, "localname": "NorthernLicenseAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_NorthernLicenseAndExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Northern license and exchange agreement.", "label": "Northern License And Exchange Agreement [Member]", "terseLabel": "Northern License And Exchange Agreement [Member]" } } }, "localname": "NorthernLicenseAndExchangeAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_NovoHoldingsASMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novo Holdings A/S.", "label": "Novo Holdings A S [Member]", "terseLabel": "Novo Holdings A/S [Member]" } } }, "localname": "NovoHoldingsASMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_NumberOfEmployeesAfterRestructuringInitiative": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Employees After Restructuring Initiative", "label": "Number Of Employees After Restructuring Initiative", "terseLabel": "Number Of Employees After Restructuring Initiative" } } }, "localname": "NumberOfEmployeesAfterRestructuringInitiative", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "spro_NumberOfEmployeesBeforeRestructuringInitiative": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Employees Before Restructuring Initiative", "label": "Number Of Employees Before Restructuring Initiative", "terseLabel": "Number Of Employees Before Restructuring Initiative" } } }, "localname": "NumberOfEmployeesBeforeRestructuringInitiative", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "spro_NumberOfOptionPeriodForFundingFromGovernmentContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of option period for funding from government contract.", "label": "Number Of Option Period For Funding From Government Contract", "terseLabel": "Number of option period for funding from government contract" } } }, "localname": "NumberOfOptionPeriodForFundingFromGovernmentContract", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "spro_NumberOfPerformanceBasedOptionSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Performance Based Option Shares.", "label": "Number Of Performance Based Option Shares [Member]", "terseLabel": "Number of Performance Based Option Shares [Member]" } } }, "localname": "NumberOfPerformanceBasedOptionSharesMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails" ], "xbrltype": "domainItemType" }, "spro_NumberOfPerformanceBasedRSUsSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Performance Based RSUs Shares.", "label": "Number Of Performance Based R S Us Shares [Member]", "terseLabel": "Performance Based RSUs Shares [Member]" } } }, "localname": "NumberOfPerformanceBasedRSUsSharesMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails" ], "xbrltype": "domainItemType" }, "spro_NumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of renewal options.", "label": "Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "NumberOfRenewalOptions", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "spro_OfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office space.", "label": "Office Space [Member]", "terseLabel": "Office Space [Member]" } } }, "localname": "OfficeSpaceMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_OperatingAndFinanceLeaseAssets": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating and finance lease assets.", "label": "Operating And Finance Lease Assets", "totalLabel": "Total leased assets" } } }, "localname": "OperatingAndFinanceLeaseAssets", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "monetaryItemType" }, "spro_OperatingLeaseBeginningDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease beginning date.", "label": "Operating Lease Beginning Date", "terseLabel": "Operating lease beginning date" } } }, "localname": "OperatingLeaseBeginningDate", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "spro_OperatingLeasePercentageOfAnnualBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease percentage of annual base rent.", "label": "Operating Lease Percentage Of Annual Base Rent", "terseLabel": "Operating lease percentage of annual base rent" } } }, "localname": "OperatingLeasePercentageOfAnnualBaseRent", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_OperatingLeasesAnnualBaseRentFinal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating leases annual base rent final.", "label": "Operating Leases Annual Base Rent Final", "terseLabel": "Operating leases annual base rent final" } } }, "localname": "OperatingLeasesAnnualBaseRentFinal", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_OperatingLeasesAnnualBaseRentInitial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating leases annual base rent initial.", "label": "Operating Leases Annual Base Rent Initial", "terseLabel": "Operating leases annual base rent initial" } } }, "localname": "OperatingLeasesAnnualBaseRentInitial", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_OperatingLeasesExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases expiration date.", "label": "Operating Leases Expiration Date", "terseLabel": "Operating lease expiration date" } } }, "localname": "OperatingLeasesExpirationDate", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "spro_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expiration year.", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "Net operating loss carryforwards expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "spro_OptionPeriodContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option period contracts.", "label": "Option Period Contracts [Member]", "terseLabel": "Option Period Contracts [Member]" } } }, "localname": "OptionPeriodContractsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_OptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase common stock.", "label": "Options To Purchase Common Stock [Member]", "terseLabel": "Options to Purchase Common Stock [Member]" } } }, "localname": "OptionsToPurchaseCommonStockMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "spro_OtherAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other assets.", "label": "Other Assets Policy [Text Block]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsPolicyTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "spro_OutstandingAccruedExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Outstanding Accrued Expense", "label": "Outstanding Accrued Expense" } } }, "localname": "OutstandingAccruedExpense", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "spro_OwnershipChangeIncreaseInOwnershipByMaximumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership change increase in ownership by maximum percentage.", "label": "Ownership Change Increase In Ownership By Maximum Percentage", "terseLabel": "Maximum increase in percentage ownership of stockholders or public groups" } } }, "localname": "OwnershipChangeIncreaseInOwnershipByMaximumPercentage", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_OwnershipChangeIncreaseInOwnershipPercentageTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership change increase in ownership percentage term.", "label": "Ownership Change Increase In Ownership Percentage Term", "terseLabel": "Ownership change, increase in ownership percentage, term" } } }, "localname": "OwnershipChangeIncreaseInOwnershipPercentageTerm", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_PatentCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent costs policy.", "label": "Patent Costs Policy Policy [Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsPolicyPolicyTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "spro_PaymentForRoyaltyLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for Royalty Liabilities", "label": "Payment for Royalty Liabilities", "terseLabel": "Less payments made" } } }, "localname": "PaymentForRoyaltyLiabilities", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "monetaryItemType" }, "spro_PaymentsForProceedsFromPropertyAndEquipment": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for proceeds from property and equipment.", "label": "Payments For Proceeds From Property and Equipment", "negatedLabel": "other" } } }, "localname": "PaymentsForProceedsFromPropertyAndEquipment", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_PercentOfAggregatePaymentReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of aggregate payment received", "label": "Percent of aggregate payment received", "terseLabel": "Percent of aggregate payment received" } } }, "localname": "PercentOfAggregatePaymentReceived", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_PercentOfMinimumAggregatePaymentReceivedThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent Of Minimum Aggregate Payment Received Threshold", "label": "Percent Of Minimum Aggregate Payment Received Threshold", "terseLabel": "Percent of minimum aggregate payment received" } } }, "localname": "PercentOfMinimumAggregatePaymentReceivedThreshold", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "spro_PercentageOfAnnualNetRevenues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual net revenues.", "label": "Percentage of annual net revenues" } } }, "localname": "PercentageOfAnnualNetRevenues", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_PercentageOfConditionalObligation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Conditional Obligation.", "label": "Percentage of Conditional Obligation", "terseLabel": "Percentage of conditional obligation in case of default" } } }, "localname": "PercentageOfConditionalObligation", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "spro_PercentageOfMinorityInvestorOutstandingSharesRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of minority investor outstanding shares repurchased.", "label": "Percentage Of Minority Investor Outstanding Shares Repurchased", "terseLabel": "Percentage of minority investor outstanding shares repurchased" } } }, "localname": "PercentageOfMinorityInvestorOutstandingSharesRepurchased", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_PercentageOfTaxBenefitRecognized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of tax benefit recognized", "label": "Percentage of tax benefit recognized" } } }, "localname": "PercentageOfTaxBenefitRecognized", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_PerformanceBasedAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-Based Awards [Member]", "label": "Performance-Based Awards [Member]" } } }, "localname": "PerformanceBasedAwardsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_PerformanceObligationAllocatedTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Performance Obligation Allocated Transaction Price", "label": "Performance Obligation Allocated Transaction Price" } } }, "localname": "PerformanceObligationAllocatedTransactionPrice", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "monetaryItemType" }, "spro_PerformanceObligationStandaloneSellingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Performance obligation standalone selling price.", "label": "Performance Obligation Standalone Selling Price", "terseLabel": "Performance Obligations, Standalone Selling Price" } } }, "localname": "PerformanceObligationStandaloneSellingPrice", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "monetaryItemType" }, "spro_PerformanceObligationsExclusiveOptionToNegotiateLicense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Performance obligations exclusive option to negotiate license.", "label": "Performance Obligations Exclusive Option To Negotiate License", "terseLabel": "Performance obligations exclusive option to negotiate license" } } }, "localname": "PerformanceObligationsExclusiveOptionToNegotiateLicense", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PerformanceObligationsRelatedToResearchAndDevelopmentServicesMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Performance obligations related to research and development services milestone.", "label": "Performance Obligations Related To Research And Development Services Milestone", "terseLabel": "Performance obligations related to research and development services milestone" } } }, "localname": "PerformanceObligationsRelatedToResearchAndDevelopmentServicesMilestone", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PeriodOfOptionGrantedOnAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of option granted on an agreement.", "label": "Period Of Option Granted On Agreement", "terseLabel": "Period of option granted on an agreement" } } }, "localname": "PeriodOfOptionGrantedOnAgreement", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_PfizerIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pfizer Inc Member.", "label": "Pfizer Inc Member", "terseLabel": "Pfizer Inc [Member]" } } }, "localname": "PfizerIncMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_PfizerLicenseAndSharePurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pfizer license and share purchase agreements member", "label": "Pfizer License and Share Purchase Agreements [Member]" } } }, "localname": "PfizerLicenseAndSharePurchaseAgreementsMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_PfizerPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pfizer purchase agreement member.", "label": "Pfizer Purchase Agreement [Member]", "terseLabel": "Pfizer Purchase Agreement [Member]" } } }, "localname": "PfizerPurchaseAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "spro_Phase3ProgrammeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase 3 Programme [Member]", "label": "Phase 3 Programme [Member]", "terseLabel": "Delivery of phase III programme" } } }, "localname": "Phase3ProgrammeMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails" ], "xbrltype": "domainItemType" }, "spro_PotentialAmountAdditionalFundingAwarded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential amount additional funding awarded.", "label": "Potential Amount Additional Funding Awarded", "terseLabel": "Potential amount additional funding awarded" } } }, "localname": "PotentialAmountAdditionalFundingAwarded", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PotentialAmountIncreaseInCommittedFunding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential amount increase in committed funding.", "label": "Potential Amount Increase In Committed Funding", "terseLabel": "Potential amount increase in committed funding" } } }, "localname": "PotentialAmountIncreaseInCommittedFunding", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PotentialAmountInitialFundingAwarded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential amount initial funding awarded.", "label": "Potential Amount Initial Funding Awarded", "terseLabel": "Potential amount initial funding awarded" } } }, "localname": "PotentialAmountInitialFundingAwarded", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PotentialContractAmountAwarded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential contract amount awarded.", "label": "Potential Contract Amount Awarded", "terseLabel": "Potential contract amount awarded" } } }, "localname": "PotentialContractAmountAwarded", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PotentialGrantAmountAwarded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential grant amount awarded.", "label": "Potential Grant Amount Awarded", "terseLabel": "Potential grant amount awarded" } } }, "localname": "PotentialGrantAmountAwarded", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PotentialGrantAmountExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential grant amount exercised.", "label": "Potential Grant Amount Exercised", "terseLabel": "Potential grant amount exercised" } } }, "localname": "PotentialGrantAmountExercised", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_PreferredStockIntrinsicValueOfBeneficialConversionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock intrinsic value of beneficial conversion feature.", "label": "Preferred Stock Intrinsic Value Of Beneficial Conversion Feature", "terseLabel": "Intrinsic value of beneficial conversion feature" } } }, "localname": "PreferredStockIntrinsicValueOfBeneficialConversionFeature", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ProceedsFromGovernmentContract": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from government contract", "label": "Proceeds From Government Contract", "terseLabel": "Committed amount from government contract", "verboseLabel": "Committed amount from government contract" } } }, "localname": "ProceedsFromGovernmentContract", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ProceedsFromIssuanceFollowOnPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance follow-on public offering.", "label": "Proceeds From Issuance Follow On Public Offering", "terseLabel": "Net proceeds from issuance of common and preferred stock" } } }, "localname": "ProceedsFromIssuanceFollowOnPublicOffering", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ProceedsFromIssuanceFollowOnPublicOfferingGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance follow on public offering gross.", "label": "Proceeds From Issuance Follow On Public Offering Gross", "terseLabel": "Gross proceeds from issuance of common and preferred stock" } } }, "localname": "ProceedsFromIssuanceFollowOnPublicOfferingGross", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ProceedsFromIssuanceOfCommonStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock gross.", "label": "Proceeds From Issuance Of Common Stock Gross", "terseLabel": "Gross proceeds from issuance of common stock", "verboseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGross", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ProceedsFromIssuanceOfCommonStockGrossUponSatisfactionOfCertainCondition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock gross upon satisfaction of certain condition.", "label": "Proceeds From Issuance Of Common Stock Gross Upon Satisfaction Of Certain Condition", "terseLabel": "Gross proceeds from issuance of common stock upon Satisfaction of certain conditions" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGrossUponSatisfactionOfCertainCondition", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ProceedsFromSaleOfFutureRoyaltiesNet": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of future royalties, net", "label": "Proceeds from sale of future royalties, net", "terseLabel": "Proceeds from sale of future royalties, net" } } }, "localname": "ProceedsFromSaleOfFutureRoyaltiesNet", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_PropertyPlantAndEquipmentEstimatedUseFulLive": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Plant And Equipment Estimated Use ful Live", "label": "Property Plant And Equipment Estimated Use ful Live", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUseFulLive", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "stringItemType" }, "spro_ReceivableAmountUponAchievementOfCertainMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Receivable amount upon achievement of certain milestone.", "label": "Receivable Amount Upon Achievement Of Certain Milestone", "terseLabel": "Receivable amount upon achievement of certain milestone" } } }, "localname": "ReceivableAmountUponAchievementOfCertainMilestone", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ReductionToResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction to research and development expense.", "label": "Reduction To Research And Development Expense", "verboseLabel": "Reduction to research and development expense" } } }, "localname": "ReductionToResearchAndDevelopmentExpense", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ReimbursementToLandlord": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reimbursement to landlord.", "label": "Reimbursement To Landlord", "terseLabel": "Amount reimbursed" } } }, "localname": "ReimbursementToLandlord", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_RemainingTransactionPriceAllocatedToPerformanceObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining Transaction price allocated to performance obligations.", "label": "Remaining Transaction Price Allocated To Performance Obligations" } } }, "localname": "RemainingTransactionPriceAllocatedToPerformanceObligations", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_RepaymentOfLiabilityRelatedToTheSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of liability related to the sale of future royalties", "label": "Repayment of liability related to the sale of future royalties", "negatedLabel": "Repayment of liability related to the sale of future royalties", "terseLabel": "Repayment of liability related to the sale of future royalties" } } }, "localname": "RepaymentOfLiabilityRelatedToTheSaleOfFutureRoyalties", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_RepurchaseOfNoncontrollingInterestPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase of noncontrolling interest price per share.", "label": "Repurchase Of Noncontrolling Interest Price Per Share", "terseLabel": "Repurchase price per share" } } }, "localname": "RepurchaseOfNoncontrollingInterestPricePerShare", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "spro_ResearchAndDevelopmentServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development services.", "label": "Research And Development Services [Member]", "terseLabel": "Research and Development Services [Member]" } } }, "localname": "ResearchAndDevelopmentServicesMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "domainItemType" }, "spro_ResearchAndDevelopmentServicesRelatedToUpcomingMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Services Related To Upcoming Milestones [Member]", "label": "Research And Development Services Related To Upcoming Milestones [Member]" } } }, "localname": "ResearchAndDevelopmentServicesRelatedToUpcomingMilestonesMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_ResearchAndDevelopmentTaxIncentiveTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research and development tax incentive.", "label": "Research And Development Tax Incentive [Text Block]", "terseLabel": "Australia Research and Development Tax Incentive" } } }, "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentive" ], "xbrltype": "textBlockItemType" }, "spro_RestructuringChargesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring charges table text block", "label": "Restructuring charges table text block", "terseLabel": "Schedule Restructuring charges" } } }, "localname": "RestructuringChargesTableTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringTables" ], "xbrltype": "textBlockItemType" }, "spro_RestructuringPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring policies for the company.", "label": "Restructuring [Policy Text block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringPolicyTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "spro_RevenueInterestFinancingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement member.", "label": "Revenue Interest Financing Agreement [Member]" } } }, "localname": "RevenueInterestFinancingAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_RevenueInterestFinancingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing text block.", "label": "Revenue Interest Financing Text Block", "terseLabel": "Liability Related to the Sale of Future Royalties" } } }, "localname": "RevenueInterestFinancingTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyalties1" ], "xbrltype": "textBlockItemType" }, "spro_RevenuePerformanceObligationsRecognitionMethodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue performance obligations recognition method description.", "label": "Revenue Performance Obligations Recognition Method Description", "terseLabel": "Performance Obligations, Recognition Method" } } }, "localname": "RevenuePerformanceObligationsRecognitionMethodDescription", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "stringItemType" }, "spro_RightOfUseAssetsAndLeaseObligationsRecordedUponCommencementOrAmendmentOfLeaseAgreements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-use assets and lease obligations recorded upon commencement or amendment of lease agreements.", "label": "Right Of Use Assets And Lease Obligations Recorded Upon Commencement Or Amendment Of Lease Agreements", "terseLabel": "Right-of-use assets and lease obligations recorded upon commencement or amendment of lease agreements" } } }, "localname": "RightOfUseAssetsAndLeaseObligationsRecordedUponCommencementOrAmendmentOfLeaseAgreements", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_RoyaltyIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty issuance cost.", "label": "Royalty issuance cost", "terseLabel": "Less initial issuance costs (recorded as discount)", "verboseLabel": "Royalty issuance cost" } } }, "localname": "RoyaltyIssuanceCost", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "monetaryItemType" }, "spro_RoyaltyLiabilityBeginningBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Liability Beginning Balance", "label": "Royalty Liability Beginning Balance", "periodStartLabel": "Liability related to sale of future royalties, beginning balance" } } }, "localname": "RoyaltyLiabilityBeginningBalance", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "monetaryItemType" }, "spro_RoyaltyLiabilityEndingBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Liability Ending Balance", "label": "Royalty Liability Ending Balance", "periodEndLabel": "Liability related to sale of future royalties, ending balance" } } }, "localname": "RoyaltyLiabilityEndingBalance", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "monetaryItemType" }, "spro_RoyaltyPayments": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty payments.", "label": "Royalty Payments", "negatedLabel": "Royalty payments" } } }, "localname": "RoyaltyPayments", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_SPRSevenFourOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPR 741.", "label": "S P R Seven Four One [Member]", "terseLabel": "SPR 741 [Member]", "verboseLabel": "SPR Seven Four One [Member]" } } }, "localname": "SPRSevenFourOneMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_SPRTwoZeroSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPR 206.", "label": "S P R Two Zero Six [Member]", "terseLabel": "SPR206 [Member]", "verboseLabel": "SPR Two Zero Six [Member]" } } }, "localname": "SPRTwoZeroSixMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement [Member]" } } }, "localname": "SalesAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_SalesMilestoneEvents": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales milestone events", "label": "Sales milestone events", "terseLabel": "Sales milestone events" } } }, "localname": "SalesMilestoneEvents", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "spro_SaviorServiceAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Savior service agreement.", "label": "Savior Service Agreement [Member]", "terseLabel": "Savior Service Agreement [Member]" } } }, "localname": "SaviorServiceAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued expenses and other current liabilities table.", "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "spro_ScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyalties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Changes in the Liability Related to the Sale of Future Royalties", "label": "Schedule of Changes in the Liability Related to the Sale of Future Royalties", "terseLabel": "Schedule of Changes in the Liability Related to the Sale of Future Royalties" } } }, "localname": "ScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyalties", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesTables" ], "xbrltype": "textBlockItemType" }, "spro_ScheduleOfIncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of income tax.", "label": "Schedule Of Income Tax [Line Items]", "terseLabel": "Schedule Of Income Tax [Line Items]" } } }, "localname": "ScheduleOfIncomeTaxLineItems", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_ScheduleOfIncomeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Income Tax [Table]", "label": "Schedule Of Income Tax [Table]", "terseLabel": "Schedule Of Income Tax [Table]" } } }, "localname": "ScheduleOfIncomeTaxTable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_ScheduleOfLeaseBalancesRelatedToOperatingAndFinanceLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of lease balances related to operating and finance leases.", "label": "Schedule Of Lease Balances Related To Operating And Finance Leases Table [Text Block]", "terseLabel": "Summary of Lease Balances Related to Operating and Finance Leases Except Weighted Average Remaining Lease Term And Discount Rate" } } }, "localname": "ScheduleOfLeaseBalancesRelatedToOperatingAndFinanceLeasesTableTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "spro_ScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of performance obligation along with standalone selling price and transaction price allocated.", "label": "Schedule Of Performance Obligation Along With Standalone Selling Price And Transaction Price Allocated Table Text Block", "terseLabel": "Schedule of Performance Obligation Along with Standalone Selling Price and Transaction Price Allocated" } } }, "localname": "ScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedTableTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsTables" ], "xbrltype": "textBlockItemType" }, "spro_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]", "terseLabel": "Summary of Supplemental Cash Flow Information Related to Operating Leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "spro_SecondOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second option.", "label": "Second Option [Member]", "terseLabel": "Second Option [member]" } } }, "localname": "SecondOptionMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_SeriesABCAndDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A B C and D convertible preferred stock.", "label": "Series A B C And D Convertible Preferred Stock [Member]", "terseLabel": "Series A, B, C and D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesABCAndDConvertiblePreferredStockMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "spro_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "spro_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "spro_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C convertible preferred stock.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "spro_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Preferred Stock.", "label": "Series D Convertible Preferred Stock [Member]", "terseLabel": "Series D Preferred Stock [Member]", "verboseLabel": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "spro_ServiceAgreementAdditionalPaymentRelatedToFacilityBuildOutCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Service agreement additional payment related to facility build out costs.", "label": "Service Agreement Additional Payment Related To Facility Build Out Costs", "terseLabel": "Service agreement additional payment related to facility build out costs" } } }, "localname": "ServiceAgreementAdditionalPaymentRelatedToFacilityBuildOutCosts", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueRollforwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Rollforwards", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueRollforwards", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "stringItemType" }, "spro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestEqualMonthlyInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, equal monthly installments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Equal Monthly Installments", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Equal Monthly Installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestEqualMonthlyInstallments", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "spro_ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToReceiveShareNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, right to receive share number.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Right to Receive Share, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Right to Receive Share, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRightToReceiveShareNumber", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "spro_ShareBasedCompensationAwardPerformanceBasedVestingCriteriaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award performance based vesting criteria.", "label": "Share Based Compensation Award Performance Based Vesting Criteria [Member]", "terseLabel": "Performance-based Vesting Criteria [Member]" } } }, "localname": "ShareBasedCompensationAwardPerformanceBasedVestingCriteriaMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "spro_ShareBasedCompensationAwardPerformanceBasedVestingCriteriaOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award performance based vesting criteria one.", "label": "Share Based Compensation Award Performance Based Vesting Criteria One [Member]", "terseLabel": "Performance-based Vesting Criteria 1 [Member]" } } }, "localname": "ShareBasedCompensationAwardPerformanceBasedVestingCriteriaOneMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_ShareBasedCompensationAwardPerformanceBasedVestingCriteriaTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award performance based vesting criteria two.", "label": "Share Based Compensation Award Performance Based Vesting Criteria Two [Member]", "terseLabel": "Performance-based Vesting Criteria 2 [Member]" } } }, "localname": "ShareBasedCompensationAwardPerformanceBasedVestingCriteriaTwoMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesToBeIncremented": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, maximum number of shares to be incremented.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Number Of Shares To Be Incremented", "terseLabel": "Number of shares to be incremented" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesToBeIncremented", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "spro_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfOutstandingStockMaximumToBeIncremented": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum to be incremented.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Percentage Of Outstanding Stock Maximum To Be Incremented", "terseLabel": "Percentage of outstanding shares of common stock to be incremented" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfOutstandingStockMaximumToBeIncremented", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_SperoCantabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spero Cantab.", "label": "Spero Cantab [Member]", "terseLabel": "Spero Cantab [Member]" } } }, "localname": "SperoCantabMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_SperoGyraseINCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spero Gyrase, Inc.", "label": "Spero Gyrase I N C [Member]", "terseLabel": "Spero Gyrase, Inc. [Member]" } } }, "localname": "SperoGyraseINCMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "spro_SperoTherapeuticsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spero Therapeutics LLC [Member]", "label": "Spero Therapeutics LLC [Member]", "terseLabel": "Spero Therapeutics LLC [Member]" } } }, "localname": "SperoTherapeuticsLlcMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_StatetaxCreditCarryforward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "StateTax credit carryforward", "label": "StateTax credit carryforward", "terseLabel": "StateTax credit carryforward" } } }, "localname": "StatetaxCreditCarryforward", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_SublicenceFeePaidToCounterParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sublicence Fee Paid to Counter Party", "label": "Sublicence Fee Paid to Counter Party", "terseLabel": "Sublicence Fee Paid" } } }, "localname": "SublicenceFeePaidToCounterParty", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_SublicenseFeePayableToCounterparty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sublicense fee payable to counterparty.", "label": "Sublicense Fee Payable To Counterparty", "terseLabel": "Sublicense fee payable to counter party" } } }, "localname": "SublicenseFeePayableToCounterparty", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "spro_TaxCreditCarryforwardExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforward expiration period.", "label": "Tax Credit Carryforward Expiration Period", "terseLabel": "Tax credit carryforward expiration period" } } }, "localname": "TaxCreditCarryforwardExpirationPeriod", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "spro_TaxCutsAndJobsActOf2017NetOperatingLossesLimitationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax cuts and jobs act of 2017 net operating losses limitation percentage.", "label": "Tax Cuts And Jobs Act Of2017 Net Operating Losses Limitation Percentage", "terseLabel": "Tax cut and jobs act net operating loss deduction limitation percentage" } } }, "localname": "TaxCutsAndJobsActOf2017NetOperatingLossesLimitationPercentage", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "spro_TaxIncentiveReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax incentive receivable.", "label": "Tax Incentive Receivable", "terseLabel": "Tax incentive receivable" } } }, "localname": "TaxIncentiveReceivable", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_TaxIncentiveReceivableCurrent": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax incentive receivable current.", "label": "Tax Incentive Receivable Current", "terseLabel": "Tax incentive receivable, current" } } }, "localname": "TaxIncentiveReceivableCurrent", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "spro_TaxIncentiveReceivableNoncurrent": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax incentive receivable noncurrent.", "label": "Tax Incentive Receivable Noncurrent", "terseLabel": "Tax incentive receivable" } } }, "localname": "TaxIncentiveReceivableNoncurrent", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "spro_TaxIncentiveResearchAndDevelopmentActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax incentive research and development activities.", "label": "Tax Incentive Research And Development Activities", "terseLabel": "Reduction to research and development expenses" } } }, "localname": "TaxIncentiveResearchAndDevelopmentActivities", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_TebipenemHbrProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tebipenem HBr Program [Member]", "label": "Tebipenem HBr Program [Member]" } } }, "localname": "TebipenemHbrProgramMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "spro_TransactionCostsFromSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction costs from sale of future royalties", "label": "Transaction costs from sale of future royalties", "terseLabel": "Transaction costs from sale of future royalties" } } }, "localname": "TransactionCostsFromSaleOfFutureRoyalties", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "spro_TransactionPriceAllocatedToPerformanceObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transaction price allocated to performance obligations.", "label": "Transaction Price Allocated To Performance Obligations", "terseLabel": "Performance Obligations, Transaction Price Allocated", "verboseLabel": "Transaction price allocated to the performance obligations" } } }, "localname": "TransactionPriceAllocatedToPerformanceObligations", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "monetaryItemType" }, "spro_TwoThousandAndNineteenInducementEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and nineteen Inducement equity incentive plan.", "label": "Two Thousand And Nineteen Inducement Equity Incentive Plan [Member]", "terseLabel": "2019 Inducement Plan [Member]" } } }, "localname": "TwoThousandAndNineteenInducementEquityIncentivePlanMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "spro_TwoThousandSeventeenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen stock incentive plan.", "label": "Two Thousand Seventeen Stock Incentive Plan [Member]", "terseLabel": "2017 Plan [Member]" } } }, "localname": "TwoThousandSeventeenStockIncentivePlanMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "spro_TwoThousandsAndSeventeenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousands and seventeen stock incentive plan member.", "label": "Two Thousands And Seventeen Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandsAndSeventeenStockIncentivePlanMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_USDepartmentOfDefenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Department of Defense.", "label": "U S Department Of Defense [Member]", "terseLabel": "U.S. Department of Defense [Member]" } } }, "localname": "USDepartmentOfDefenseMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_USREIFCentralPlazaMassachusettsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. REIF Central Plaza Massachusetts LLC.", "label": "U S R E I F Central Plaza Massachusetts L L C [Member]", "terseLabel": "U.S. REIF Central Plaza Massachusetts, LLC [Member]" } } }, "localname": "USREIFCentralPlazaMassachusettsLLCMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "spro_UnderwrittenOfferingExercisableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten offering exercisable term.", "label": "Underwritten Offering Exercisable Term", "terseLabel": "Underwritten offering, exercisable term" } } }, "localname": "UnderwrittenOfferingExercisableTerm", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "spro_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten public offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Proceeds from the issuance of common stock related to the GSK Share Purchase Agreement" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "domainItemType" }, "spro_UnrecognizedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "unrecognized compensation expense", "label": "unrecognized compensation expense", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "UnrecognizedCompensationExpense", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_UpfrontLicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront license fee.", "label": "Upfront License Fee", "terseLabel": "Upfront license fee" } } }, "localname": "UpfrontLicenseFee", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "spro_ValuationAllowanceDeferredTaxAssetDecreaseInAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation allowance deferred tax asset decrease in amount.", "label": "Valuation Allowance Deferred Tax Asset Decrease In Amount", "terseLabel": "Decreases recorded as benefit to income tax provision" } } }, "localname": "ValuationAllowanceDeferredTaxAssetDecreaseInAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "spro_ValuationAllowanceDeferredTaxAssetIncreaseInAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation allowance deferred tax asset increase in amount.", "label": "Valuation Allowance Deferred Tax Asset Increase In Amount", "negatedLabel": "Increases recorded to income tax provision" } } }, "localname": "ValuationAllowanceDeferredTaxAssetIncreaseInAmount", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "spro_VertexLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vertex license agreement.", "label": "Vertex License Agreement [Member]", "terseLabel": "Vertex License Agreement [Member]" } } }, "localname": "VertexLicenseAgreementMember", "nsuri": "http://sperotherapeutics.com/20221231", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r220", "r476", "r477", "r480", "r481", "r558", "r627", "r704", "r707", "r708" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r220", "r476", "r477", "r480", "r481", "r558", "r627", "r704", "r707", "r708" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r217", "r218", "r339", "r345", "r632", "r634" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r326", "r327", "r328", "r329", "r390", "r566", "r598", "r628", "r629", "r643", "r651", "r660", "r709", "r762", "r763", "r764", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r326", "r327", "r328", "r329", "r390", "r566", "r598", "r628", "r629", "r643", "r651", "r660", "r709", "r762", "r763", "r764", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r282", "r567", "r644", "r658", "r701", "r702", "r712", "r770" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r282", "r567", "r644", "r658", "r701", "r702", "r712", "r770" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r326", "r327", "r328", "r329", "r372", "r390", "r422", "r423", "r424", "r565", "r566", "r598", "r628", "r629", "r643", "r651", "r660", "r699", "r709", "r763", "r764", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r326", "r327", "r328", "r329", "r372", "r390", "r422", "r423", "r424", "r565", "r566", "r598", "r628", "r629", "r643", "r651", "r660", "r699", "r709", "r763", "r764", "r765", "r766", "r767" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r217", "r218", "r339", "r345", "r633", "r634" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r391", "r694" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r238", "r391", "r673", "r694" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r283", "r284", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r645", "r659", "r712" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r283", "r284", "r613", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r645", "r659", "r712" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r238", "r391", "r673", "r674", "r694" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r715", "r756", "r757", "r758" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Spero Potentiator Australia Pty Limited [Member]" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU No. 2016-12 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU No. 2016-13 [Member]" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201815Member": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update 2018-15 [Member]", "terseLabel": "ASU No. 2018-15 [Member]" } } }, "localname": "AccountingStandardsUpdate201815Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201818Member": { "auth_ref": [ "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.", "label": "Accounting Standards Update 2018-18 [Member]", "terseLabel": "ASU No. 2018-18 [Member]" } } }, "localname": "AccountingStandardsUpdate201818Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r9", "r657" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r42" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of premium (discount) on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "spro_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r72", "r184" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r22", "r23", "r191", "r591", "r606", "r610" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive gain (loss)", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r20", "r23", "r128", "r555", "r601", "r602", "r682", "r683", "r684", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r4" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r431", "r432", "r433", "r690", "r691", "r692", "r750" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r174", "r175", "r176", "r177", "r178", "r225", "r226", "r227", "r228", "r238", "r286", "r287", "r296", "r297", "r298", "r299", "r301", "r302", "r431", "r432", "r433", "r451", "r452", "r453", "r454", "r466", "r467", "r468", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r507", "r508", "r510", "r511", "r512", "r513", "r514", "r515", "r527", "r528", "r531", "r532", "r533", "r534", "r550", "r551", "r552", "r553", "r554", "r555", "r569", "r570", "r571", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r103", "r104", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Compensation expense recognized" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestment": { "auth_ref": [ "r496", "r503" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.", "label": "Alternative Investment", "terseLabel": "Alternative investment" } } }, "localname": "AlternativeInvestment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilution rights outstanding" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of office space" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r41", "r70" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment of assets", "totalLabel": "Asset Impairment Charges, Total", "verboseLabel": "Loss related to write off" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r152", "r163", "r186", "r213", "r267", "r276", "r280", "r291", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r476", "r480", "r506", "r657", "r705", "r706", "r760" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Lease Assets and Liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r180", "r192", "r213", "r291", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r476", "r480", "r506", "r657", "r705", "r706", "r760" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r145" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total cash equivalents and marketable securities" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r59" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r60" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r290", "r303" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r58", "r289", "r303", "r586" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r465", "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r119", "r120", "r465", "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format.", "label": "Business Acquisition, Date of Acquisition Agreement", "terseLabel": "Merger date" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Merger effective date" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Repurchase ownership percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Employee related termination costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r49", "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r611", "r612", "r657", "r675" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r43", "r182", "r631" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail": { "order": 0.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents", "verboseLabel": "Total cash" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r37", "r43", "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r37", "r149" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r174", "r175", "r224", "r286", "r287", "r293", "r294", "r295", "r296", "r297", "r451", "r466", "r467", "r482", "r484", "r485", "r495", "r507", "r509", "r510", "r511", "r514", "r515", "r527", "r530", "r531", "r532", "r533", "r550", "r551", "r569", "r570", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r174", "r175", "r286", "r287", "r293", "r294", "r295", "r296", "r297", "r451", "r466", "r467", "r468", "r482", "r484", "r485", "r486", "r489", "r495", "r507", "r509", "r510", "r511", "r514", "r515", "r527", "r530", "r531", "r532", "r533", "r550", "r551", "r569", "r570", "r599", "r600", "r693" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r225", "r237", "r288", "r300", "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r187", "r188", "r189", "r213", "r242", "r243", "r246", "r248", "r255", "r256", "r291", "r330", "r332", "r333", "r334", "r337", "r338", "r343", "r344", "r347", "r351", "r359", "r506", "r630", "r672", "r687", "r695" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r469", "r470", "r474" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License, Collaboration and Service Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r15", "r155", "r168" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r76", "r324", "r325", "r614", "r703" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r690", "r691", "r750" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares/units issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r3", "r84" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares/units outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r3", "r657" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 52,456,195 shares issued and outstanding as of December 31, 2022 and 32,393,738 shares issued and outstanding as of December 31, 2021", "totalLabel": "Common Stock, Value, Issued, Total", "verboseLabel": "Common stock to be issued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r24", "r199", "r201", "r207", "r587", "r592" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Software and Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r162", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk and of Significant Suppliers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk": { "auth_ref": [ "r148", "r162" ], "lang": { "en-us": { "role": { "documentation": "Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.", "label": "Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk", "terseLabel": "Off-balance sheet risk description" } } }, "localname": "ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r127", "r636" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractorsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contractors [Abstract]" } } }, "localname": "ContractorsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNewIssuance": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "A description of the new financial instrument issued in a noncash (or part noncash) conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, New Issuance" } } }, "localname": "ConversionOfStockNewIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r1", "r2", "r85", "r88", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Number of shares issuable upon conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bonds [Member]" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Costs and Expenses, Related Party", "terseLabel": "Related Party Costs" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r13", "r150", "r342" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "terseLabel": "Debt securities, available-for-sale, unrealized gains (losses)", "totalLabel": "Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r698" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue Arrangement, by Type [Table]" } } }, "localname": "DeferredRevenueArrangementByTypeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Revenue Arrangement [Line Items]" } } }, "localname": "DeferredRevenueArrangementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r677" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current", "totalLabel": "Deferred Revenue, Current, Total" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r678" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, non-current", "totalLabel": "Deferred Revenue, Noncurrent, Total" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r446" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r744" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r114", "r745" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r114", "r745" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Federal net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r114", "r745" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Foreign net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Federal net operating loss carryforwards, not subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r114", "r745" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Federal net operating loss carryforwards, subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r114", "r745" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r113", "r114", "r745" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Research and development tax credit carryforwards", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r447" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "negatedPeriodEndLabel": "Valuation allowance as of end of year", "negatedPeriodStartLabel": "Valuation allowance as of beginning of year", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": { "auth_ref": [ "r114", "r745" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.", "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs", "terseLabel": "Capitalized research and development expenses" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Matching contributions to 401(k) plan" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r41", "r265" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "verboseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r748" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Change in fair value of derivative liability", "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r193", "r194", "r505", "r634" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedLabel": "Less initial derivative liability (recorded as discount)", "terseLabel": "Derivative liability", "totalLabel": "Derivative Liability, Total", "verboseLabel": "Less initial derivative liability (recorded as discount)" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability [Abstract]", "terseLabel": "Derivative liabilities:" } } }, "localname": "DerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r193" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r132", "r133", "r135", "r136", "r141", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "verboseLabel": "Derivative Liability" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DescriptionOfNetInvestmentHedgeActivity": { "auth_ref": [ "r132", "r133", "r134", "r135", "r139", "r140" ], "lang": { "en-us": { "role": { "documentation": "Contains all pertinent information about an entity's hedges of the foreign currency exposure of net investments in foreign operations.", "label": "Description of Net Investment Hedge Activity", "terseLabel": "Description of net investment hedge activity" } } }, "localname": "DescriptionOfNetInvestmentHedgeActivity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r396", "r427", "r428", "r430", "r435", "r652" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal [Member]", "verboseLabel": "Domestic Country [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarliestTaxYearMember": { "auth_ref": [ "r743" ], "lang": { "en-us": { "role": { "documentation": "Earliest identified tax year.", "label": "Earliest Tax Year [Member]", "terseLabel": "Earliest Tax Year [Member]" } } }, "localname": "EarliestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r208", "r229", "r230", "r231", "r232", "r233", "r239", "r242", "r246", "r247", "r248", "r252", "r493", "r494", "r588", "r593", "r638" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic", "totalLabel": "Earnings Per Share, Basic, Total" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r208", "r229", "r230", "r231", "r232", "r233", "r242", "r246", "r247", "r248", "r252", "r493", "r494", "r588", "r593", "r638" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share,diluted", "totalLabel": "Net loss per share attributable to common stockholders, basic and diluted", "verboseLabel": "Net loss per share attributable to common stockholders, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r249", "r250", "r251", "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r440" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r215", "r440", "r459" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Federal statutory income tax rate", "terseLabel": "Federal corporate income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r742", "r746" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Increase in deferred tax asset valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r742", "r746" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r742", "r746" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Nondeductible items", "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r742", "r746" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r742", "r746" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "Federal and state research and development tax credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "auth_ref": [ "r749" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.", "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "terseLabel": "Fair value of the derivative liability", "totalLabel": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total" } } }, "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "spro_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related expenses", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost related to unvested share-based awards", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option [Member]", "verboseLabel": "Stock Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]" } } }, "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r84", "r176", "r203", "r204", "r205", "r221", "r222", "r223", "r226", "r234", "r236", "r254", "r299", "r360", "r431", "r432", "r433", "r453", "r454", "r492", "r520", "r521", "r522", "r523", "r524", "r525", "r555", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of excess stock shares permitted to be issued.", "label": "Excess Stock, Shares Authorized", "terseLabel": "Increase in shares authorized" } } }, "localname": "ExcessStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r497", "r498", "r502" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r145", "r147" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r340", "r374", "r375", "r376", "r377", "r378", "r379", "r498", "r562", "r563", "r564", "r641", "r642", "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r497", "r498", "r499", "r500", "r504" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset": { "auth_ref": [ "r505" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.", "label": "Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset", "terseLabel": "Off-balance sheet risk" } } }, "localname": "FairValueDisclosureOffbalanceSheetRisksAmountAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements and Marketable Securities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r340", "r374", "r379", "r498", "r562", "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r340", "r374", "r379", "r498", "r563", "r641", "r642", "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r340", "r374", "r375", "r376", "r377", "r378", "r379", "r498", "r564", "r641", "r642", "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Transfer of financial asset into level 3 of fair value", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Transfer of financial liabilities into level 3 of fair value", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r340", "r374", "r375", "r376", "r377", "r378", "r379", "r562", "r563", "r564", "r641", "r642", "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r501", "r504" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r536", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance lease liability", "totalLabel": "Finance Lease, Liability, Total" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease liability.", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r535" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail": { "order": 1.0, "parentTag": "spro_OperatingAndFinanceLeaseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Financing", "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r304", "r305", "r306", "r307", "r568", "r572" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r516", "r517", "r518", "r519" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Unrealized foreign currency transaction loss", "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Office Furniture and Equipment [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FuturePolicyBenefitsLiabilityPolicy": { "auth_ref": [ "r595", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption.", "label": "Liability for Future Policy Benefit [Policy Text Block]", "verboseLabel": "Liability Related To The Sale of Future Royalties" } } }, "localname": "FuturePolicyBenefitsLiabilityPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r41", "r158" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain (Loss) on Sale of Derivatives", "negatedLabel": "Change in fair value of derivative liabilities", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r41", "r78", "r79" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of liability related to the sale of future royalties", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant [Member]" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLeasehold": { "auth_ref": [ "r41", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.", "label": "Impairment of Leasehold", "terseLabel": "Lease impairment expense" } } }, "localname": "ImpairmentOfLeasehold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r69", "r74" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r214", "r458" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail2": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r25", "r151", "r156", "r170", "r267", "r275", "r279", "r281", "r589", "r640" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r214", "r458" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail2": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r310", "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r215", "r441", "r444", "r449", "r456", "r460", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r216", "r235", "r236", "r266", "r439", "r457", "r461", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefits for the net operating losses", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r202", "r437", "r438", "r444", "r445", "r448", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r40" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r686" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r635" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue, current and non-current" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "negatedLabel": "Other long-term liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r40" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "totalLabel": "Increase (Decrease) in Other Operating Assets, Total" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r40" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r40" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r32", "r264" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r497" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Total marketable securities", "totalLabel": "Investments, Fair Value Disclosure, Total" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure [Abstract]", "terseLabel": "Marketable securities:" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LatestTaxYearMember": { "auth_ref": [ "r743" ], "lang": { "en-us": { "role": { "documentation": "Latest identified tax year.", "label": "Latest Tax Year [Member]", "terseLabel": "Latest Tax Year [Member]" } } }, "localname": "LatestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAgreementsMember": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.", "label": "Lease Agreements [Member]", "terseLabel": "Lease Agreements [Member]" } } }, "localname": "LeaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r547", "r656" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total operating lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r754" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Components of Operating Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseIncentiveReceivableCurrent": { "auth_ref": [ "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Lease Incentive Receivable, Current", "terseLabel": "Leasehold improvements receivable from the Landlord" } } }, "localname": "LeaseIncentiveReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of Maturity of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r548" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r10", "r213", "r291", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r477", "r480", "r481", "r506", "r639", "r705", "r760", "r761" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r8", "r154", "r166", "r657", "r688", "r697", "r751" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r12", "r181", "r213", "r291", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r477", "r480", "r481", "r506", "r657", "r705", "r760", "r761" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Derivative liabilities", "totalLabel": "Liabilities, Fair Value Disclosure, Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": { "auth_ref": [ "r759" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of early contract termination fees included in liabilities subject to compromise.", "label": "Liabilities Subject to Compromise, Early Contract Termination Fees", "terseLabel": "Contract termination fees" } } }, "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "verboseLabel": "Collaboration Revenue [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Manufacturing Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r19", "r153", "r165", "r213", "r291", "r330", "r332", "r333", "r334", "r337", "r338", "r506" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "terseLabel": "Non-controlling interest", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r92", "r125", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Purchase of non-controlling interest" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "Non-Controlling Interests" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r19", "r28", "r124", "r129" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Minority Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r210" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r210" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r39", "r42" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r42", "r157", "r169", "r179", "r198", "r200", "r205", "r213", "r225", "r229", "r230", "r231", "r232", "r235", "r236", "r244", "r267", "r275", "r279", "r281", "r291", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r494", "r506", "r640", "r705" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "totalLabel": "Net Income (Loss) Attributable to Parent, Total" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r229", "r230", "r231", "r232", "r239", "r240", "r245", "r248", "r267", "r275", "r279", "r281", "r640" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r123", "r360", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r267", "r275", "r279", "r281", "r640" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r542", "r656" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Fixed operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r752" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Lease impairment" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r536" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r536" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r536" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r538", "r544" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r535" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail": { "order": 0.0, "parentTag": "spro_OperatingAndFinanceLeaseAssets", "weight": 1.0 }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r546", "r656" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r545", "r656" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseBalancesRelatedToOperatingAndFinanceLeasesExceptWeightedAverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r80", "r142", "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]", "terseLabel": "Option Indexed to Issuer's Equity, Type" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "spro_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r185" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r195", "r196", "r197" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities", "totalLabel": "Unrealized gain (loss) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive gain (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r195", "r197" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "verboseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-Term Debt, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Long-term Asset [Member]", "verboseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r190" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r41" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Spero Therapeutics, Inc. Stockholders' Equity (Deficit) [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r313", "r685" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "terseLabel": "Payments made" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringScheduleOfRestructuringChargesIncludedInAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "terseLabel": "Payments of financing costs", "totalLabel": "Payments of Financing Costs, Total" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r36" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs", "terseLabel": "Payment of offering costs", "verboseLabel": "Aggregate issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r57" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "totalLabel": "Payments to Acquire Marketable Securities, Total" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r372", "r373", "r379", "r380", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r392", "r648" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Retirement Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockAccretionOfRedemptionDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of accretion of the preferred stock redemption discount during the period.", "label": "Preferred Stock, Accretion of Redemption Discount", "terseLabel": "Accretion of beneficial conversion feature" } } }, "localname": "PreferredStockAccretionOfRedemptionDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r2", "r85" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred Stock, Conversion Basis", "terseLabel": "Preferred stock, conversion basis" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Deemed Dividend" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r2", "r85", "r86", "r687", "r710" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred stock, liquidation per share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r2", "r343" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r2", "r343" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares/units issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares/units outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r2", "r657" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 3,218,152 shares issued and outstanding as of December 31, 2021", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r2", "r85" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights", "terseLabel": "Voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r681" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r35" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of common stock to related party", "verboseLabel": "Proceeds from the issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRoyaltiesReceived": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for royalties during the current period.", "label": "Proceeds from Royalties Received", "terseLabel": "Proceeds from sale of future royalties, gross" } } }, "localname": "ProceedsFromRoyaltiesReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable securities", "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r35", "r102" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r179", "r198", "r200", "r209", "r213", "r225", "r235", "r236", "r267", "r275", "r279", "r281", "r291", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r475", "r478", "r479", "r494", "r506", "r589", "r640", "r654", "r655", "r684", "r705" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "negatedTotalLabel": "Net loss", "netLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r75", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r71", "r183" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r73", "r167", "r590", "r657" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r73", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Components of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r381", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r173", "r556", "r557", "r758" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r381", "r556", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r758" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement with Federal Government [Abstract]" } } }, "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r106", "r171", "r768" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]", "verboseLabel": "Research and Development Expenses [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureAustraliaResearchAndDevelopmentTaxIncentiveAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Unvested Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r311", "r313", "r316", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r41", "r317", "r319", "r700" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charge to expense", "totalLabel": "Restructuring", "verboseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringScheduleOfRestructuringChargesIncludedInAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r312", "r313", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r313", "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring Reserve, Ending Balance", "periodStartLabel": "Restructuring Reserve, Beginning Balance", "totalLabel": "Restructuring Reserve, Total" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringScheduleOfRestructuringChargesIncludedInAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r313", "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "terseLabel": "Write-offs and impairments" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringScheduleOfRestructuringChargesIncludedInAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r5", "r92", "r164", "r605", "r610", "r657" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r176", "r221", "r222", "r223", "r226", "r234", "r236", "r299", "r431", "r432", "r433", "r453", "r454", "r492", "r601", "r603" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r262", "r263", "r274", "r277", "r278", "r282", "r283", "r285", "r369", "r370", "r567" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Revenue recognized" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r371", "r637" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition - Collaboration Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones.", "label": "Revenue Recognition, Milestone Method [Table Text Block]", "terseLabel": "Schedule of remaining potential milestone payments" } } }, "localname": "RevenueRecognitionMilestoneMethodTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r206", "r213", "r262", "r263", "r274", "r277", "r278", "r282", "r283", "r285", "r291", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r506", "r589", "r705" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Grant revenue", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_RightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A security giving shareholders entitlement to acquire new shares issued by the entity at an established price in proportion to the number of shares already owned. Generally, rights expire within in a short time after issuance.", "label": "Rights [Member]", "terseLabel": "Proceeds from the issuance of common stock, net of commissions" } } }, "localname": "RightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Plus Interest expense accrued/ recognized" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesScheduleOfChangesInTheLiabilityRelatedToTheSaleOfFutureRoyaltiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyGuaranteesCommitmentsAmount": { "auth_ref": [ "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount the entity has committed to make for future royalty guarantees.", "label": "Royalty Guarantees, Commitments, Amount", "terseLabel": "Liability related to sale of future royalty" } } }, "localname": "RoyaltyGuaranteesCommitmentsAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Shares Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary of Gross Unrealized Gains and Losses of Marketable Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r61", "r62", "r63", "r64", "r65", "r66", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfRemainingPotentialMilestonePaymentsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Net Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Share-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Describes the details pertaining to each employee stock ownership plan.", "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]" } } }, "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r689" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Domestic and Foreign Components of Loss before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetComponentsOfPropertyAndEquipmentNetDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r312", "r313", "r314", "r315", "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r393", "r395", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r95", "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Assumptions Used to Determine Fair Value of Stock Option Awards Granted to Employees and Directors" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r81", "r82", "r83", "r85", "r86", "r87", "r89", "r90", "r91", "r92", "r187", "r188", "r189", "r255", "r343", "r344", "r345", "r347", "r351", "r357", "r359", "r643", "r672", "r687" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r676" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r268", "r269", "r270", "r271", "r272", "r273", "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeparateAccountLiabilityPremium": { "auth_ref": [ "r771" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow to separate account liability from premium collected from policyholder.", "label": "Separate Account, Liability, Premium", "terseLabel": "Associated premium as a freestanding equity-linked instrument under ASC 815" } } }, "localname": "SeparateAccountLiabilityPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r679", "r680", "r711" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r41" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails": { "order": 0.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and other employee costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Disclosure [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Options vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted shares in addition to stock option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsUsedToDetermineFairValueOfStockOptionAwardsGrantedToEmployeesAndDirectorsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsUsedToDetermineFairValueOfStockOptionAwardsGrantedToEmployeesAndDirectorsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsUsedToDetermineFairValueOfStockOptionAwardsGrantedToEmployeesAndDirectorsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Common stock available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited or cancelled", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "verboseLabel": "Share based compensation options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value of awards granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding as of December 31, 2022", "periodStartLabel": "Outstanding as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding as of December 31, 2022", "periodStartLabel": "Outstanding as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Exercisable at December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Outstanding as of December 31, 2022 - vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Outstanding as of December 31, 2022 - vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Outstanding as of December 31, 2022 - vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r400", "r419", "r420", "r421", "r422", "r425", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.", "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "terseLabel": "Summary of Activity of Options and RSUs of Performance-Based Options" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of incentive units vesting" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfAssumptionsUsedToDetermineFairValueOfStockOptionAwardsGrantedToEmployeesAndDirectorsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant-date fair value of awards forfeited or cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Grant Date Fair Value of Outstanding as of December 31, 2022", "periodStartLabel": "Weighted Average Grant Date Fair Value of Outstanding as of December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding as of December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at December 31, 2022" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding as of December 31, 2022 - vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Vested and released", "terseLabel": "Vested and released" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant-date fair value of awards vested and released" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Exercise price per share of stock options as a percentage of fair market value of share of common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Share price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49", "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State [Member]", "verboseLabel": "State And Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r187", "r188", "r189", "r213", "r242", "r243", "r246", "r248", "r255", "r256", "r291", "r330", "r332", "r333", "r334", "r337", "r338", "r343", "r344", "r347", "r351", "r359", "r506", "r630", "r672", "r687", "r695" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r84", "r176", "r203", "r204", "r205", "r221", "r222", "r223", "r226", "r234", "r236", "r254", "r299", "r360", "r431", "r432", "r433", "r453", "r454", "r492", "r520", "r521", "r522", "r523", "r524", "r525", "r555", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r221", "r222", "r223", "r254", "r567" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r17", "r84", "r85", "r92", "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r2", "r3", "r84", "r92" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock and preferred stock net of offering costs, shares", "verboseLabel": "Issuance of stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r2", "r3", "r84", "r92", "r406" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "terseLabel": "Issuance of common stock upon the exercise of stock options, shares", "verboseLabel": "Stock option exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionGrantedUnderEquityIncentivePlansDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r18", "r84", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock", "verboseLabel": "Issuance of Common Stock, conversion of Preferred Stock to Common Stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsRightsOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r2", "r3", "r84", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock and preferred stock net of offering costs and issuance costs", "verboseLabel": "Common stock issued, aggregate fair value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r2", "r3", "r84", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Number of common stock award shares granted" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r18", "r84", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r3", "r6", "r7", "r56", "r657", "r688", "r697", "r751" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r123", "r124", "r130", "r176", "r177", "r204", "r221", "r222", "r223", "r226", "r234", "r299", "r360", "r431", "r432", "r433", "r453", "r454", "r492", "r520", "r521", "r525", "r555", "r602", "r603", "r688", "r697", "r751" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSHARESANDSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r93", "r212", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r358", "r360", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r526", "r560" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r526", "r560" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r526", "r560" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r526", "r560" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r559", "r561" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityTransactionsUnderwrittenPublicOfferingAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Summary of Changes in Valuation Allowance for Deferred Tax Assets" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of non-cash activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r45", "r46", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Supplemental Deferred Purchase Price", "terseLabel": "Purchase price" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNonControllingInterestsSperoGyraseAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r174", "r175", "r176", "r177", "r178", "r225", "r226", "r227", "r228", "r238", "r286", "r287", "r296", "r297", "r298", "r299", "r301", "r302", "r431", "r432", "r433", "r451", "r452", "r453", "r454", "r466", "r467", "r468", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r507", "r508", "r510", "r511", "r512", "r513", "r514", "r515", "r527", "r528", "r531", "r532", "r533", "r534", "r550", "r551", "r552", "r553", "r554", "r555", "r569", "r570", "r571", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureLiabilityRelatedToTheSaleOfFutureRoyaltiesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureGovernmentContractsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLicenseCollaborationAndServiceAgreementsScheduleOfPerformanceObligationAlongWithStandaloneSellingPriceAndTransactionPriceAllocatedDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r312", "r313", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/DisclosureRestructuringRestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service [Extensible Enumeration]", "terseLabel": "Type of Revenue [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r769" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. Government Securities [Member]" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfGrossUnrealizedGainsAndLossesOfMarketableSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r436", "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties related to uncertain tax positions", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r52", "r53", "r54", "r257", "r258", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r543", "r656" ], "calculation": { "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable operating lease expense" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionsAndRsusOfPerformanceBasedOptionsDetails", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r241", "r248" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r239", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sperotherapeutics.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "http://sperotherapeutics.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e845-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e848-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c),(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)(6)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14937-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r661": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r662": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r663": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r664": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r665": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r666": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r667": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r668": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r669": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r671": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "15", "Topic": "815", "URI": "https://asc.fasb.org/subtopic&trid=2229187", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56015-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }